GeneDx Holdings Corp.

GeneDx Holdings Corp., trading under ticker CMLF, is the post-merger successor to CM Life Sciences III Inc., a special purpose acquisition company that completed its IPO in 2021. Sponsored by CM Life Sciences, a vehicle affiliated with Casdin Capital and Corvex Management, the SPAC completed its business combination with GeneDx, a rare disease genomics and diagnostics company formerly held by OPKO Health, in 2022. The 8-K filed on April 17, 2023 reflects routine post-merger corporate reporting obligations. GeneDx operates in the healthcare and genomic diagnostics sector, with a focus on whole exome and genome sequencing for rare pediatric diseases. Sign up for SpacDesk to access full filing history, sponsor profiles, and deal data on CMLF and thousands of other SPACs.